Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice

Journal of the American College of Cardiology

Volumn 57, Issue 15, 2011, Pages 1611-1621

  Merki, Esther ^a   Graham, Mark ^b   Taleb, Adam ^a   Leibundgut, Gregor ^a   Yang, Xiaohong ^a   Miller, Elizabeth R ^a   Fu, Wuxia ^b   Mullick, Adam E ^b   Lee, Richard ^b   Willeit, Peter ^a,c   Crooke, Rosanne M ^b   Witztum, Joseph L ^a   Tsimikas, Sotirios ^a,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antisense oligonucleotides; atherosclerosis; lipoprotein (a); lipoproteins; oxidation; oxidized phospholipids

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN A; APOLIPOPROTEIN B; LIPOPROTEIN A; TETRANECTIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GENETIC RISK; HISTOPATHOLOGY; KIDNEY FUNCTION TEST; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER FUNCTION TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TARGETING; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOPROTEIN(A); CHOLESTEROL; KIDNEY; KRINGLES; LIPOPROTEIN(A); LIVER; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; OXIDATION-REDUCTION; PHOSPHOLIPIDS; TRIGLYCERIDES;

EID: 79953699040     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.10.052     Document Type: Article

References (28)

1. E. Anuurad, M.B. Boffa, M.L. Koschinsky, and L. Berglund Lipoprotein(a): a unique risk factor for cardiovascular disease Clin Lab Med 26 2006 751 772 (Pubitemid 44716507)
2. R.M. Lawn, N.W. Boonmark, and K. Schwartz The recurring evolution of lipoprotein(a) J Biol Chem 270 1995 24004 24009
3. R. Guerra, Z. Yu, S.M. Marcovina, R. Peshock, J.C. Cohen, and H.H. Hobbs Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study Circulation 111 2005 1471 1479 (Pubitemid 40470640)
4. G. Utermann Genetic architecture and evolution of the lipoprotein(a) trait Curr Opin Lipidol 10 1999 133 141 (Pubitemid 29187096)
5. M.L. Rand, W. Sangrar, and M.A. Hancock Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN Arterioscler Thromb Vasc Biol 18 1998 1393 1399 (Pubitemid 28421876)
6. S. Tsimikas, and J.L. Witztum The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity Curr Opin Lipidol 19 2008 369 377
7. S. Tsimikas, P. Clopton, and E.S. Brilakis Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study Circulation 119 2009 1711 1719
8. A. Bennet, E. Di Angelantonio, and S. Erqou Lipoprotein(a) levels and risk of future coronary heart disease: Large-scale prospective data Arch Intern Med 168 2008 598 608 (Pubitemid 351468395)
9. The Emerging Risk Factors Collaboration Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JAMA 302 2009 412 423
10. S. Erqou, A. Thompson, and E. Di Angelantonio Apolipoprotein(a) isoforms and the risk of vascular disease: Systematic review of 40 studies involving 58,000 participants J Am Coll Cardiol 55 2010 2160 2167
11. P.R. Kamstrup, A. Tybjaerg-Hansen, R. Steffensen, and B.G. Nordestgaard Genetically elevated lipoprotein(a) and increased risk of myocardial infarction JAMA 301 2009 2331 2339
12. R. Clarke, J.F. Peden, and J.C. Hopewell Genetic variants associated with Lp(a) lipoprotein level and coronary disease N Engl J Med 361 2009 2518 2528
13. F. Akdim, E.S. Stroes, and E.J. Sijbrands Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy J Am Coll Cardiol 55 2010 1611 1618
14. M. Schneider, J.L. Witztum, and S.G. Young High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins J Lipid Res 46 2005 769 778 (Pubitemid 43073287)
15. E. Merki, M.J. Graham, and A.E. Mullick Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice Circulation 118 2008 743 753
16. K.A. Frazer, G. Narla, J.L. Zhang, and E.M. Rubin The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice Nat Genet 9 1995 424 431
17. R.M. Crooke, M.J. Graham, K.M. Lemonidis, C.P. Whipple, S. Koo, and R.J. Perera An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis J Lipid Res 46 2005 872 884
18. P.A. Teivainen, K.A. Eliassen, E.M. Rubin, S. Djurovic, and K. Berg Human apoB contributes to increased serum total apo(a) level in LPA transgenic mice Lipids Health Dis 3 2004 8
19. C. Bergmark, A. Dewan, and A. Orsoni A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma J Lipid Res 49 2008 2230 2239
20. H.H. Hobbs, and A.L. White Lipoprotein(a): intrigues and insights Curr Opin Lipidol 10 1999 225 236 (Pubitemid 29405913)
21. W.J. Cain, J.S. Millar, and A.S. Himebauch Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a] J Lipid Res 46 2005 2681 2691 (Pubitemid 43107480)
22. M.M. Luke, J.P. Kane, and D.M. Liu A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease Arterioscler Thromb Vasc Biol 27 2007 2030 2036 (Pubitemid 47312314)
23. D.I. Chasman, D. Shiffman, and R.Y.L. Zee Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy Atherosclerosis 203 2009 371 376
24. K.A. Whitehead, R. Langer, and D.G. Anderson Knocking down barriers: advances in siRNA delivery Nat Rev Drug Discov 8 2009 129 138
25. S. Tsimikas, Z. Mallat, and P.J. Talmud Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events J Am Coll Cardiol 56 2010 946 955
26. S. Tsimikas, E.S. Brilakis, and E.R. Miller Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease N Engl J Med 353 2005 46 57 (Pubitemid 41007806)
27. K. Arai, M.M. Luke, and M.L. Koschinsky The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles Atherosclerosis 209 2010 498 503
28. T. Seimon, M.J. Nodolski, and X. Liao Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress Cell Metab 12 2010 467 482